ZA200705982B - Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-3,3-dimethylpiperazine - Google Patents

Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-3,3-dimethylpiperazine

Info

Publication number
ZA200705982B
ZA200705982B ZA200705982A ZA200705982A ZA200705982B ZA 200705982 B ZA200705982 B ZA 200705982B ZA 200705982 A ZA200705982 A ZA 200705982A ZA 200705982 A ZA200705982 A ZA 200705982A ZA 200705982 B ZA200705982 B ZA 200705982B
Authority
ZA
South Africa
Prior art keywords
phenylin
dimethylpiperazine
dan
trans
chloro
Prior art date
Application number
ZA200705982A
Other languages
English (en)
Inventor
Bang-Andersen Benny
Lopez De Diego Heidi
Original Assignee
Lundebeck As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200705982(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundebeck As H filed Critical Lundebeck As H
Publication of ZA200705982B publication Critical patent/ZA200705982B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200705982A 2005-02-16 2006-02-14 Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-3,3-dimethylpiperazine ZA200705982B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500239 2005-02-16

Publications (1)

Publication Number Publication Date
ZA200705982B true ZA200705982B (en) 2009-06-24

Family

ID=37908539

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705982A ZA200705982B (en) 2005-02-16 2006-02-14 Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-3,3-dimethylpiperazine

Country Status (29)

Country Link
US (2) US7648991B2 (uk)
EP (1) EP1853576B1 (uk)
JP (1) JP5055135B2 (uk)
KR (1) KR101386387B1 (uk)
CN (1) CN101119983B (uk)
AR (1) AR052909A1 (uk)
AT (1) ATE515501T1 (uk)
AU (1) AU2006215957B9 (uk)
BR (1) BRPI0607436B8 (uk)
CA (1) CA2597622C (uk)
CY (1) CY1111857T1 (uk)
DK (1) DK1853576T3 (uk)
EA (1) EA017631B1 (uk)
ES (1) ES2368786T3 (uk)
HK (1) HK1117525A1 (uk)
HR (1) HRP20110645T1 (uk)
IL (1) IL184551A (uk)
MX (1) MX2007009980A (uk)
MY (1) MY148683A (uk)
NO (1) NO339863B1 (uk)
NZ (1) NZ556397A (uk)
PL (1) PL1853576T3 (uk)
PT (1) PT1853576E (uk)
RS (1) RS51944B (uk)
SI (1) SI1853576T1 (uk)
TW (1) TWI376373B (uk)
UA (1) UA95901C2 (uk)
WO (1) WO2006086986A1 (uk)
ZA (1) ZA200705982B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544715A (en) * 2003-08-18 2009-09-25 Lundbeck & Co As H Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
EA018927B1 (ru) * 2008-05-07 2013-11-29 Х. Лундбекк А/С Способ лечения когнитивного расстройства, ассоциированного с шизофренией
BRPI0919165A2 (pt) * 2008-10-03 2015-12-08 Lundbeck & Co As H composição farmacêutica,e, uso de um composto
AU2012273657B2 (en) 2011-06-20 2016-07-21 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
EP3873885A1 (en) 2018-10-29 2021-09-08 H. Lundbeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2122820A1 (en) 1991-11-05 1993-05-13 Russell Donavan Cousins Endothelin receptor antagonists
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
JPH06184132A (ja) 1992-12-22 1994-07-05 Kotobuki Seiyaku Kk ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤
CA2176500C (en) 1993-11-30 1999-09-28 George J. Quallich Process for preparing a chiral tetralone
CA2132411A1 (en) 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US5807897A (en) 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
ATE255555T1 (de) * 1998-05-01 2003-12-15 Pfizer Prod Inc Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
NZ508790A (en) 1998-05-22 2003-10-31 Scios Inc Heterocyclic compounds and methods to treat cardiac failure and other disorders
DE19824470A1 (de) 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
FR2786769B1 (fr) 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
JP2000351773A (ja) 1999-06-08 2000-12-19 Yamanouchi Pharmaceut Co Ltd フラン誘導体からなる医薬
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
IN187170B (uk) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
NZ544715A (en) 2003-08-18 2009-09-25 Lundbeck & Co As H Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
JP2008530039A (ja) 2005-02-16 2008-08-07 ハー・ルンドベック・アクチエゼルスカベット トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩

Also Published As

Publication number Publication date
MX2007009980A (es) 2007-09-26
EA017631B1 (ru) 2013-02-28
JP2008530040A (ja) 2008-08-07
KR20070103414A (ko) 2007-10-23
ATE515501T1 (de) 2011-07-15
CA2597622C (en) 2013-11-12
RS51944B (en) 2012-02-29
EA200701740A1 (ru) 2007-12-28
EP1853576B1 (en) 2011-07-06
BRPI0607436B1 (pt) 2020-10-06
JP5055135B2 (ja) 2012-10-24
WO2006086986A1 (en) 2006-08-24
DK1853576T3 (da) 2011-09-26
US7648991B2 (en) 2010-01-19
NO20074639L (no) 2007-09-12
KR101386387B1 (ko) 2014-04-25
CY1111857T1 (el) 2015-11-04
US8450324B2 (en) 2013-05-28
HK1117525A1 (en) 2009-01-16
ES2368786T3 (es) 2011-11-22
TWI376373B (en) 2012-11-11
SI1853576T1 (sl) 2011-11-30
UA95901C2 (en) 2011-09-26
NZ556397A (en) 2010-06-25
PL1853576T3 (pl) 2011-12-30
EP1853576A1 (en) 2007-11-14
PT1853576E (pt) 2011-09-28
CA2597622A1 (en) 2006-08-24
AU2006215957B2 (en) 2011-09-29
MY148683A (en) 2013-05-31
AU2006215957A1 (en) 2006-08-24
US20100105699A1 (en) 2010-04-29
NO339863B1 (no) 2017-02-13
US20080153848A1 (en) 2008-06-26
AU2006215957B9 (en) 2012-02-16
BRPI0607436A2 (pt) 2010-04-06
AR052909A1 (es) 2007-04-11
IL184551A0 (en) 2007-10-31
CN101119983A (zh) 2008-02-06
BRPI0607436B8 (pt) 2021-05-25
HRP20110645T1 (hr) 2011-10-31
CN101119983B (zh) 2014-11-12
IL184551A (en) 2014-05-28
TW200640890A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
HK1123544A1 (en) Process for making trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3- dimethylpiperazine
IL184551A0 (en) Crystalline base of trans -1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
EP1844003A4 (en) NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
IL173589A0 (en) Trans-1 (6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
GB0504314D0 (en) Novel polymorph
EP1968608A4 (en) PRACTICAL, COST-EFFECTIVE SYNTHESIS OF UBICHINONES
ZA200801708B (en) Synthesis of 1±-fluoro-25-hydroxy-16-23E-diene-26,27-bishomo-20-EPI-cholecalciferol
IL184531A0 (en) Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
IS8264A (is) Trans-1(6-klór-3-fenýlindan-1-ýl)-3,3-dímetýlpíperasín
AU2004100238A4 (en) Tacomate-taco holder
AU2004907292A0 (en) Support assembly
AU2005904904A0 (en) Snap Cap
AU2005901288A0 (en) New Compound
AU2005901287A0 (en) New Compound
ZAA200500821S (en) Lamp base
AU2004901919A0 (en) New Compound
AU2004903491A0 (en) New Compound
AU2004902161A0 (en) New Compound
AU2004906673A0 (en) New Compound
AU2006901800A0 (en) Base assembly for frame
AU2004900341A0 (en) New Compounds
AU2005906443A0 (en) Support Pole
AU2004900071A0 (en) Pager
AU2004900660A0 (en) Sign holder
AU2005901445A0 (en) Support